Versus Arthritis Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chesterfield United Kingdom (2018)

Organization Overview

First Clinical Trial
2018
NCT01021735
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Arthritis Research UK | Arthritis Research UK Pain Centre | Versus Arthritis

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 3)

Antiphospholipid Syndrome (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Carpal Tunnel Syndrome (Phase 4)

Chronic Pain (Phase 4)

Granulomatosis with Polyangiitis (Phase 3)

Microscopic Polyangiitis (Phase 3)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Syndrome (Phase 4)

Systemic Vasculitis (Phase 3)

Vasculitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 17